Table 1.
Completed and ongoing clinical trials combining macrophage reprogramming and PD-L1/PD-1 blockade in cancer therapy.
| Macrophage reprogramming | PD-L1/PD-1 blockade | Cancer types | Clinical phase | Status/outcomes | Clinical trial identifier | |
|---|---|---|---|---|---|---|
| CSF1R inhibitors | PLX3397 | Durvalumab | Metastatic/advanced pancreatic or colorectal cancers | I | Completed (no results) | NCT02777710 |
| SNDX-6352 | Durvalumab | Unresectable intrahepatic cholangiocarcinoma | II | Recruiting | NCT04301778 | |
| ARRY-382 | Pembrolizumab | Advanced solid tumors | Ib/II | Completed (no results) | NCT02880371 | |
| DCC-3014 | Avelumab | Advanced or metastatic sarcomas | I | Recruiting | NCT04242238 | |
| BLZ945 | PDR001 | Advanced solid tumors | I/II | Recruiting | NCT02829723 | |
| CSF1R mAb | Cabiralizumab | Nivolumab | Peripheral T-cell lymphoma | II | Active (no results) | NCT03927105 |
| LY3022855 | Durvalumab | Advanced solid tumors | I | Completed (no results) | NCT02718911 | |
| Emactuzumab | Atezolizumab | Solid cancers | I | Completed (no results) | NCT02323191 | |
| CSF1 mAb | PD-0360324 | Avelumab | Advanced cancer | Ib/II | Recruiting | NCT02554812 |
| lacnotuzumab | PDR001 | Solid tumors | I/II | Completed (no results) | NCT02807844 | |
| CSF2 | Pexa-Vec (Thymidine Kinase- Deactivated Vaccinia Virus Plus GM-CSF) | Cemiplimab | Renal cell carcinoma | Ib/IIa | Recruiting | NCT03294083 |
| CD40 agonist | Selicrelumab | Atezolizumab | Solid tumors | Ib | Completed (no results) | NCT02304393 |
| APX005M | Nivolumab | Non-small cell lung cancer or metastatic melanoma | I/II | Completed (no results) | NCT03123783 | |
| TLRs agonist | DV281 | Approved anti-PD-1 inhibitor | Advanced non-small cell lung cancer | Ib | Completed (no results) | NCT03326752 |
| BO-112 | Pembrolizumab | Melanoma | II | Recruiting | NCT04570332 | |
| VTX-2337 | Nivolumab | Squamous cell carcinoma of the head and neck | Ib | Recruiting | NCT03906526 | |
| SBT6050 | Pembrolizumab | HER2-positive solid tumors | I | Recruiting | NCT04460456 | |
| CMP-001 | Avelumab | Advanced cancer | Ib/II | Recruiting | NCT02554812 | |
| HDAC inhibitors | Entinostat | Nivolumab | Previously treated unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma | II | Active (no results) | NCT03250273 |
| Domatinostat | Avelumab | GI cancer | II | Recruiting | NCT03812796 | |
| Entinostat | Pembrolizumab | Myelodysplastic syndrome | I | Active (no results) | NCT02936752 | |
| PI3Kγ inhibitors | Copanlisib | Nivolumab | Relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer | I/II | Recruiting | NCT03711058 |
| Copanlisib | Nivolumab | Richter’s transformation or transformed indolent non-Hodgkin’s lymphoma | I | Recruiting | NCT03884998 | |